HRTX
HRTX
NASDAQ · Biotechnology

Heron Therapeutics Inc

$0.43
-0.01 (-2.00%)
As of Jun 30, 10:23 PM ET ·
Financial Highlights (FY 2026)
Revenue
172.72M
Net Income
-22,509,965
Gross Margin
73.3%
Profit Margin
-13.0%
Rev Growth
+12.9%
D/E Ratio
9.81
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 73.3% 73.3% 40.4% 40.4%
Operating Margin -9.0% -8.1% -7.6% -6.6%
Profit Margin -13.0% -12.4% -6.9% -7.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 172.72M 153.01M 36.22M 29.20M
Gross Profit 126.62M 112.17M 14.65M 11.81M
Operating Income -15,475,614 -12,338,813 -2,748,870 -1,921,517
Net Income -22,509,965 -17,947,349 -2,507,722 -2,038,148
Gross Margin 73.3% 73.3% 40.4% 40.4%
Operating Margin -9.0% -8.1% -7.6% -6.6%
Profit Margin -13.0% -12.4% -6.9% -7.0%
Rev Growth +12.9% +12.9% +20.2% -6.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 35.21M 35.21M 87.16M 81.85M
Total Equity 3.59M 3.59M 118.11M 119.94M
D/E Ratio 9.81 9.81 0.74 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -12,900,013 -10,856,672 -3,086,652 -2,725,751
Free Cash Flow -2,753,402 -2,024,759